Back to List View Graph View

KRAS

KRAS is a human gene, formally the KRAS proto-oncogene, GTPase, and also known as Kirsten rat sarcoma viral oncogene homolog.

Where the papers sit

47 papers from the last 6 months study KRAS directly · updated from PubMed 16 Nov 2026

Those 47 are all about one subject.

  • KRAS Disease Biology

    Work centers on how KRAS alterations shape tumor growth, treatment response, and therapeutic vulnerability across cancers and inflammatory disease. Resistance is linked to interferon signaling, CASTOR1 loss, and tumor context, while immune approaches include mutant p53–SPP1 modulation and TCR engagers. Drug development ranges from KRASG12C and KRASG12D inhibitors and CRBN degraders to daraxonrasib combinations and fluvoxamine repurposing. Computational prediction, multi-omics models, and phytochemical studies broaden the search, but no single strategy dominates.

    47 papers

PARADIGM SHIFT

KRAS-mutant tumors can be intrinsically resistant to KRAS inhibition because non-KRAS signaling states determine drug response

The pancreatic-cancer study of KRASG12D-mutant patient-derived organoids and the KRASG12D-driven NSCLC study of CASTOR1-deficient mice and tumor organoids separately show that KRAS mutation does not guarantee dependence on KRAS inhibition. In pancreatic cancer, suppressed interferon signaling associated with sustained MYC activity produces intrinsic resistance, which can be reversed by interferon-β; in NSCLC, CASTOR1 loss activates mTORC1 and related AKT/ERK signaling, with resistance overcome by cotargeting mTORC1 or PI3K/mTOR 42956743Oct 42913021Oct. The resulting change is from treating the KRAS allele as a sufficient predictor of response to treating tumor state and bypass circuitry as determinants requiring biomarker-guided combination therapy.

NEW DIRECTION

KRAS functions as an immunometabolic regulator of pathogenic TH17 cells in autoimmune disease

Autoimmune uveitis and experimental uveitis and colitis models treated with fluvoxamine show that GPR183-driven SOS-dependent KRAS activation in pathogenic CD4+ T cells promotes copper-overload mitochondrial stress, glycolytic rewiring, and TH17 pathogenicity, rather than serving only as a cancer-associated oncogenic driver or therapeutic target. Blocking this pathway with the GPR183 antagonist fluvoxamine attenuated disease, placing KRAS within an autoimmune immunometabolic mechanism and identifying a repurposing strategy for uveitis 42950033Oct.

Papers

The 47 papers from the last 6 months that study KRAS directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

KRAS Disease Biology (47)
  1. Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one · 11 Nov 2026 PMID 43013488
  2. KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Cancer cell · 29 Oct 2026 PMID 42956743
  3. Intrinsic resistance to KRAS inhibition: Interfering with interferon. Cancer cell · 29 Oct 2026 PMID 42956741
  4. Lipid-sensing GPR183-KRAS signaling mediates TH17 autoimmunity and identifies fluvoxamine repurposing in uveitis. Science advances · 28 Oct 2026 PMID 42950033
  5. Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
  6. CASTOR1 functional inactivation drives KRAS-mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. Science advances · 23 Oct 2026 PMID 42913021
  7. A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
  8. Exploring the cytotoxic potential of Artemisia herba-alba crude extract and key phytoconstituents using in vitro assays and molecular docking insights. PloS one · 25 Sept 2026 PMID 42789608
  9. Proteomic regulation of anti-proliferative and anti-migratory activity by potent phytochemicals from Pistacia integerrima J.L. Steward Ex Brandis via PI3K, AKT1, and KRAS for Lung Cancer. Molecular biology reports · 12 Sept 2026 PMID 42730982
  10. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  11. MCKG-SL: Knowledge graph-based multi-feature cross-aggregation synthetic lethality prediction for KRAS gene. Artificial intelligence in medicine · 10 Sept 2026 PMID 42721585
  12. Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
  13. TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
  14. KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. Science advances · 2 Sept 2026 PMID 42685218
  15. Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Anticancer research · 31 Aug 2026 PMID 42674713
  16. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
  17. One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
  18. Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer. Apoptosis : an international journal on programmed cell death · 20 Aug 2026 PMID 42622908
  19. Identification of a three-gene prognostic signature associated with tumor immune characteristics in lung adenocarcinoma: A comprehensive analysis of multi-omics data. Translational oncology · 17 Aug 2026 PMID 42607524
  20. Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study. Lung cancer (Amsterdam, Netherlands) · 17 Aug 2026 PMID 42607379
  21. Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
  22. Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles. Journal of controlled release : official journal of the Controlled Release Society · 11 Aug 2026 PMID 42580447
  23. The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
  24. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
  25. KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles' Heel in Pancreatic Cancer. Cancer research · 15 Jul 2026 PMID 42452976
  26. Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors. Journal of medicinal chemistry · 14 Jul 2026 PMID 42446418
  27. An Iridium(III) Complex Induces Immunogenic Methuosis and Reprograms Tumor-Associated Macrophages for Chemoimmunotherapy against KRAS-Mutated Tumors. Journal of medicinal chemistry · 12 Jul 2026 PMID 42437351
  28. Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy. BMC cancer · 3 Jul 2026 PMID 42399819
  29. KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. Journal of hematology & oncology · 3 Jul 2026 PMID 42393724
  30. Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma. The Journal of clinical investigation · 1 Jul 2026 PMID 42383354
  31. Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. Advances in therapy · 30 Jun 2026 PMID 42377736
  32. High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377115
  33. Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. Cancer discovery · 22 Jun 2026 PMID 42329102
  34. The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer cell · 11 Jun 2026 PMID 42276046
  35. Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses. Clinical cancer research : an official journal of the American Association for Cancer Research · 10 Jun 2026 PMID 42268349
  36. Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
  37. KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones. Cancer research · 8 Jun 2026 PMID 42258763
  38. Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy. Angewandte Chemie (International ed. in English) · 7 Jun 2026 PMID 42251661
  39. Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of medicinal chemistry · 5 Jun 2026 PMID 42247371
  40. The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation. Oncotarget · 3 Jun 2026 PMID 42233520
  41. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America · 1 Jun 2026 PMID 42224594
  42. Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research · 27 May 2026 PMID 42200804
  43. Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European journal of cancer (Oxford, England : 1990) · 26 May 2026 PMID 42190397
  44. Navigating high-order protein fitness landscapes via deep learning on directed evolution trajectories. Proceedings of the National Academy of Sciences of the United States of America · 26 May 2026 PMID 42190010
  45. Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
  46. Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer cell · 21 May 2026 PMID 42167227
  47. Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Developmental cell · 20 May 2026 PMID 42161274

By study type

Observational studies and case reports (4)
  1. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
  2. Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study. Lung cancer (Amsterdam, Netherlands) · 17 Aug 2026 PMID 42607379
  3. High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377115
  4. Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
Human data, design not indexed (8)
  1. One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. Analytical methods : advancing methods and applications · 24 Aug 2026 PMID 42635115
  2. The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. Journal of hematology & oncology · 8 Aug 2026 PMID 42571010
  3. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
  4. The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer cell · 11 Jun 2026 PMID 42276046
  5. Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses. Clinical cancer research : an official journal of the American Association for Cancer Research · 10 Jun 2026 PMID 42268349
  6. Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European journal of cancer (Oxford, England : 1990) · 26 May 2026 PMID 42190397
  7. Navigating high-order protein fitness landscapes via deep learning on directed evolution trajectories. Proceedings of the National Academy of Sciences of the United States of America · 26 May 2026 PMID 42190010
  8. Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
Preclinical: animal, cell and lab studies (27)
  1. Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one · 11 Nov 2026 PMID 43013488
  2. KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Cancer cell · 29 Oct 2026 PMID 42956743
  3. Intrinsic resistance to KRAS inhibition: Interfering with interferon. Cancer cell · 29 Oct 2026 PMID 42956741
  4. Lipid-sensing GPR183-KRAS signaling mediates TH17 autoimmunity and identifies fluvoxamine repurposing in uveitis. Science advances · 28 Oct 2026 PMID 42950033
  5. CASTOR1 functional inactivation drives KRAS-mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. Science advances · 23 Oct 2026 PMID 42913021
  6. Exploring the cytotoxic potential of Artemisia herba-alba crude extract and key phytoconstituents using in vitro assays and molecular docking insights. PloS one · 25 Sept 2026 PMID 42789608
  7. Proteomic regulation of anti-proliferative and anti-migratory activity by potent phytochemicals from Pistacia integerrima J.L. Steward Ex Brandis via PI3K, AKT1, and KRAS for Lung Cancer. Molecular biology reports · 12 Sept 2026 PMID 42730982
  8. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  9. Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720481
  10. TCR-JANUS engager proteins enable bispecific targeting to overcome tumor heterogeneity in TCR-T cell therapy. Science advances · 9 Sept 2026 PMID 42715334
  11. KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. Science advances · 2 Sept 2026 PMID 42685218
  12. Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Anticancer research · 31 Aug 2026 PMID 42674713
  13. Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer. Apoptosis : an international journal on programmed cell death · 20 Aug 2026 PMID 42622908
  14. Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
  15. Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles. Journal of controlled release : official journal of the Controlled Release Society · 11 Aug 2026 PMID 42580447
  16. KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles' Heel in Pancreatic Cancer. Cancer research · 15 Jul 2026 PMID 42452976
  17. Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors. Journal of medicinal chemistry · 14 Jul 2026 PMID 42446418
  18. An Iridium(III) Complex Induces Immunogenic Methuosis and Reprograms Tumor-Associated Macrophages for Chemoimmunotherapy against KRAS-Mutated Tumors. Journal of medicinal chemistry · 12 Jul 2026 PMID 42437351
  19. Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy. BMC cancer · 3 Jul 2026 PMID 42399819
  20. Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma. The Journal of clinical investigation · 1 Jul 2026 PMID 42383354
  21. Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. Cancer discovery · 22 Jun 2026 PMID 42329102
  22. KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones. Cancer research · 8 Jun 2026 PMID 42258763
  23. Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy. Angewandte Chemie (International ed. in English) · 7 Jun 2026 PMID 42251661
  24. Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer. Journal of medicinal chemistry · 5 Jun 2026 PMID 42247371
  25. The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation. Oncotarget · 3 Jun 2026 PMID 42233520
  26. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America · 1 Jun 2026 PMID 42224594
  27. Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer. Cancer cell · 21 May 2026 PMID 42167227
Unclassified: not yet indexed with MeSH (8)
  1. Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
  2. A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Oct 2026 PMID 42864811
  3. MCKG-SL: Knowledge graph-based multi-feature cross-aggregation synthetic lethality prediction for KRAS gene. Artificial intelligence in medicine · 10 Sept 2026 PMID 42721585
  4. Identification of a three-gene prognostic signature associated with tumor immune characteristics in lung adenocarcinoma: A comprehensive analysis of multi-omics data. Translational oncology · 17 Aug 2026 PMID 42607524
  5. KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. Journal of hematology & oncology · 3 Jul 2026 PMID 42393724
  6. Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer. Advances in therapy · 30 Jun 2026 PMID 42377736
  7. Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research · 27 May 2026 PMID 42200804
  8. Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Developmental cell · 20 May 2026 PMID 42161274